Introduction
Stroke is the third leading cause of death worldwide after Ischemic Heart Disease (IHD) and Cancer. Stroke has accounted for nearly 5.7 million deaths worldwide, 87% of these deaths occur in low and middle income countries. 1 Incidence of stroke in South Asian countries has increased by more than 100%, while this is decreased by 42% in developed European countries in last four decades. 2 Ischaemic stroke (IS) accounts for 85% of stroke and its pathophysiology are regulated by a combination of lifestyle, environmental and unclear genetic risk factors. 3 Inflammation and genetics are both prominent mechanisms in the pathogenesis of ischemic stroke. 4 Candidate genes, stroke susceptibility alleles and their association with stroke pathogenesis have been intensely studied in the last few years. 5, 6 Human Interleukin-6 (IL-6) gene is located at chromosome 7p21 which consists of 5 exons and 4 introns and synthesized as a precursor protein of 232 amino acids. 7, 8 IL-6 is a pleiotropic cytokine associated with atherosclerosis and cardiovascular disease that may also be a key mediator in the inflammatory response to ischemic stroke. 9 Two functional promoter polymorphisms, G174C and G572C have been identified in the IL-6 promoter region and these two genetic variants may be associated with
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Methods

Identification of Relevant Studies
A literature search for GAS that investigated the association between the IL-6 gene polymorphisms and susceptibility to IS published before August 30, 2014 which was conducted in the following electronic databases: PubMed, Medline and trip databases. The following combinations of main keywords were used: ('Interleukin-6' or 'IL-6') and ('ischaemic stroke or 'cerebral infarction' or 'IS') and ('genetic polymorphism' or 'single nucleotide polymorphisms' or 'SNP'). The search was done without limitations on language, but only included those studies that were conducted on human subjects. All references in eligible articles were extensively reviewed to identify additional published articles.
Inclusion and Exclusion Criteria
To be included in the analysis, eligible studies had to meet the following criteria: (a) case-control studies on the association between the IL-6 gene polymorphisms and susceptibility to IS; (b) all patients in the candidate studies meet the diagnostic criteria for IS; (c) studies with sufficient available data to calculate Odds Ratios (ORs) with corresponding 95% Confidence intervals (CIs). The major reason for excluding studies were: (i) not case-control study; (ii) duplicates publications with overlapping subjects from the same study; and (iii) no available data reported. For multiple studies using overlapping cases or controls, the most recent study with the largest sample size was included in the meta-analysis. This metaanalysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines with only slight modification, and did not require ethics board approval. 44 
Data Extraction
According to the PRISMA guidelines, two investigators independently PK and AKY checked each full-text report for eligibility and extracted the following data from eligible studies: surname of first author, year of publication, country of origin, ethnicity, number of case and control, age, sex ratio, genotyping method, allele and genotype frequency etc. Disagreements were solved by discussion between all authors until consensus was reached.
Quality Assessment
Newcastle-Ottawa Scale (NOS) criteria 45 were used to assess the qualities of all included studies. The NOS criteria use a ''star'' rating system to judge methodological quality based on three aspects of a study: selection, comparability, and exposure. Scores range from 0 stars (worst) to 9 stars (best), with a score of 5 or higher indicating a moderate-high methodological quality. Two authors independently assessed the quality of included studies. Discrepancies over quality scores were resolved by discussion with all authors and subsequent consensus.
Statistical Analysis
Genotype distributions in the controls were tested for conformation to Hardy-Weinberg equilibrium (HWE) using the chisquare test. HWE in the controls was tested by comparing the expected and observed genotype frequencies using the Pearson chi-square test for goodness of fit. The association between the IL-6 gene polymorphisms and susceptibility to IS was assessed by the pooled odds ratios (ORs) with their corresponding 95% confidence intervals (95%CIs) under three genetic models, including dominant, recessive and allelic model. Taking into consideration possible between-study heterogeneity, a statistical test for heterogeneity was first conducted using Cochran's Q statistic and the I 2 metric. We considered the presence of significant heterogeneity at the 10% level of significance and values of I 2 exceeding 50% as an indicator of significant heterogeneity. When no heterogeneity was found with P.0.10 or I 2 < 50%, a fixed-effects model was used to estimate the pooled ORs and 95%CIs. Otherwise, a random-effects model was applied. In addition to an overall comparison, stratified analyses, based on ethnicity, source of control, HWE status, and genotyping method where applicable, were also performed to explore possible explanations of between-study heterogeneity and to investigate whether overall reported associations were present in subgroups. Begg's funnel plot was used to assess the potential for publication bias.
Results
Figure-1 represents a flow diagram of retrieved and excluded studies with their reasons for exclusion. A total of 285 relevant papers were identified using the pre-specified search strategy. In accordance with the inclusion criteria, 16 case-control studies were included for IL-6 G174C with a total of 3317 IS patients and 3482 healthy controls and 3 case control studies for IL-6 G572C with a total of 1814 IS patients and 3219 healthy controls in this meta-analysis. For IL-6 G174C, studies were conducted in two major ethnic populations, with nine including Asians and seven as Caucasians. The publication duration of included studies ranged from 2002 to 2014. The characteristics and methodological quality of all included studies are summarized in Table-1 .
Association between the IL-6 G174C Polymorphism and Susceptibility to IS
Sixteen case-control studies [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] investigated the relationship between G174C and susceptibility to IS with a total of 3317 IS patients and 3432 healthy controls. Since between-study heterogeneity obviously existed (P<0.10 and I 2 >50% under all genetic models), the random-effect model was used. As shown in Figure-2 , no significant association was found under dominant 
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Association between the IL-6 G572C Polymorphism and Susceptibility to IS
Three case-control studies had investigated the relationship between G572C 28,30,41 and susceptibility to IS with a total of 1814 IS patients and 3219 healthy controls. Since betweenstudy heterogeneity obviously existed (P<0.10 and I 2 >50% under all genetic models), the random-effects model was used. Overall, the IL-6 G572C polymorphism was not significantly as- 
discussion
This study was designed to advance the understanding of association between the IL-6 G174C and G572C gene polymorphism and risk of ischaemic stroke. In this meta-analysis, 17 studies (16 studies for G174C, 3 studies for G572C) on IL-6 polymorphisms were performed to provide the most comprehensive assessment of the association between the polymorphisms and IS risk. Our data did not support a genetic association between the polymorphisms and IS risk in populations.
This meta-analysis must be interpreted with caution because of certain limitations. First, the outcomes were based on individual unadjusted ORs, whereas a more precise evaluation should be adjusted by potentially suspected factors, including age, gender, smoking status, and environmental factors. Second, these estimations were obtained by pooling the studies with regard to heterogeneity. However, heterogeneity provided the opportunity to identify factors that modified the genotype. Our meta analysis show heterogeneity except in dominant model of quality studies and some of the factors identified are age, sex, quality of studies and risk factors for ischaemic stroke which could not be stratified in our metaanalysis due to lack of raw data in studies. Pooling studies with different results lead to a high degree of heterogeneity, but might result in hazardous or invalid estimates. Finally, we cannot exclude the possibility that the results were biased because of undetected stratification in the original case-control samples.
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In summary, the present meta-analyses did not support a prominent association of the IL-6 promoter polymorphisms (G174C and G572C) with IS risk. However, the G174C polymorphism might be associated with IS in Asian studies based on sampled studies. More convincing evidence is required to conclude about the relation between these polymorphisms and risk of IS.
Conclusion
Well designed studies are needed to investigate the association of polymorphisms in IL6 larger and various ancestry populations. 
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